Diabetes in Cardiovascular Disease: A Companion to Braunwald's Heart Disease
Darren K McGuire
Format: PDF / Kindle (mobi) / ePub
Diabetes in Cardiovascular Disease is a current, expert resource focusing on the complex challenges of providing cardiovascular care to patients with diabetes. Designed as a companion to Braunwald’s Heart Disease, this interdisciplinary medical reference book bridges the gap between the cardiology and endocrinology communities of scientists and care providers, and highlights the emerging scientific and clinical topics that are relevant for cardiologists, diabetologists/endocrinologists, and the extended diabetes care team.
- Access essential coverage of basic and clinical sciences
- Take advantage of a format that follows that of the well-known and internationally recognized Braunwald’s Heart Disease.
- Review the best available clinical data and pragmatic recommendations for the prevention and management of cardiovascular complications of diabetes; national/societal intervention strategies to curb the growing prevalence of diabetes; and the current pathophysiological understanding of cardiovascular comorbidities in patients with diabetes.
- Consult this title on your favorite e-reader, conduct rapid searches, and adjust font sizes for optimal readability.
, complemented by an expanded focus on epidemiology, behavioral sciences, health policy, and disparities in health care.
Although cell biologic approaches and animal models have provided key scientific insights into atherogenesis, ongoing efforts are directed toward translating these findings to human disease. The identification of stable, circulating biomarkers of inflammation has allowed investigators to test prospectively how indices of inflammation relate to atherosclerosis disease burden and clinical events, including responses to current agents and therapies under development. PPARs have been extensively
who were randomized to aspirin 650 mg daily or placebo.9 Although aspirin did not reduce the primary endpoint of all-cause death (hazard ratio [HR] 0.91, 95% confidence interval [CI] 0.75-1.11), a favorable trend was observed toward a reduction in fatal or nonfatal myocardial infarction (MI) at 5 years that did not achieve statistical significance (HR 0.83, 95% CI 0.66-1.04).9 In contrast, a benefit for aspirin could not be definitively demonstrated in diabetic patients enrolled in the Primary
McDonnell ME, Akhtar S. Creating a perioperative glycemic control program. Anesthesiol Res Pract. 2011;46:59. 107 McDonnell ME, Alexanian SM, White L, Lazar HL. A primer for achieving glycemic control in the cardiac surgical patient. J Card Surg. 2012;27:470. 108 Friedberg SJ, Lan YW, Blum JJ, Gregerman RI. Insulin absorption: a major factor in apparent insulin resistance and the control of type 2 diabetes mellitus. Metabolism. 2006;55:614. 109 Varghese P, Gleason V, Sorokin R, et al.
3 traits220.127.116.11Plus 4 traits4.04.23.8Overall MetS74.473.275.8 Data from Hanefeld M, Koehler C, Gallo S, et al: Impact of the individual components of the metabolic syndrome and their different combinations on the prevalence of atherosclerotic vascular disease in type 2 diabetes: the Diabetes in Germany (DIG) study, Cardiovasc Diabetol 6:13, 2007. HDL-C = high-density lipoprotein cholesterol; HTG = hypertriglyceridemia; NCEP-ATP III = National Cholesterol Education Program—Adult Treatment
K, Heier M, et al. Prevalence of undiagnosed diabetes and impaired glucose regulation in 35-59-year-old individuals in Southern Germany: the KORA F4 Study. Diabet Med. 2011;27:360–362. 9 Hanefeld M, Ceriello A, Schwarz PE, et al. The metabolic syndrome–a postprandial disease? Horm Metab Res. 2006;38:435–436. 10 Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care.